hims & hers health experienced a significant 28% drop in shares following disappointing financial results, raised concerns over its weight loss business, and has decided to discontinue some products due to supply resolution.

Shares fell 28% after disappointing quarterly results.

CFO who discussed the company's glp-1 offering performance.

CEO who addressed future options for customers.

Company that produces glp-1 weight loss medications Ozempic and Wegovy.